Maryland Researchers Use xCELLigence System to Study Role of "Microtentacles" in Breast Cancer
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center have studied the involvement of “microtentacles,” or extensions of the plasma membrane of breast cancer cells, in how cancers spread to distant locations in the body.
Targeting these microtentacles might prove to be a new way to prevent or slow the growth of these secondary cancers, scientists say. The researchers used Roche’s xCELLigence RTCA SP Instrument to measure attachment as the relative impedance change, cell index, across the microelectronic sensors at the bottom of the system´s E-Plates.
The cytoskeletal organization of detached and circulating tumor cells (CTCs) is currently not well defined and may provide potential targets for new therapies to limit metastatic tumor spread. CTCs reattach in vivo in distant tissues by a mechanism that is tubulin-dependent and suppressed by polymerized actin.
The cytoskeletal mechanisms that promote reattachment of CTCs match exactly with the mechanisms supporting tubulin microtentacles (McTN), which the researchers have recently identified in detached breast tumor cells. The new study aimed to investigate how McTN formation is affected by the microtubule-associated protein, tau, which is expressed in a subset of chemotherapy-resistant breast cancers.
The results show that endogenous tau protein localizes to McTNs and is both necessary and sufficient to promote McTN extension in detached breast tumor cells. Tau-induced McTNs increase reattachment of suspended cells and retention of CTCs in lung capillaries.
Analysis of individual-matched primary and metastatic tumors reveals that 52% possess tau-expression in metastases and 26% display significantly increased tau-expression over disease progression. Tau-enrichment in metastatic tumors and the ability of tau to promote tumor cell reattachment through McTN formation support a model in which tau-induced microtubule stabilization provides a selective advantage during tumor metastasis.
“We hope that through our research, we will be able to identify drugs that will target the growth of these microtentacles and help to stop the spread of the original cancer. Drugs that reduce tau expression may hold potential to inhibit tumor metastasis,” says the senior author, Stuart S. Martin, PhD, a researcher at the University of Maryland Greenebaum Cancer Center and associate professor of physiology at the University of Maryland School of Medicine.
Targeting these microtentacles might prove to be a new way to prevent or slow the growth of these secondary cancers, scientists say. The researchers used Roche’s xCELLigence RTCA SP Instrument to measure attachment as the relative impedance change, cell index, across the microelectronic sensors at the bottom of the system´s E-Plates.
The cytoskeletal organization of detached and circulating tumor cells (CTCs) is currently not well defined and may provide potential targets for new therapies to limit metastatic tumor spread. CTCs reattach in vivo in distant tissues by a mechanism that is tubulin-dependent and suppressed by polymerized actin.
The cytoskeletal mechanisms that promote reattachment of CTCs match exactly with the mechanisms supporting tubulin microtentacles (McTN), which the researchers have recently identified in detached breast tumor cells. The new study aimed to investigate how McTN formation is affected by the microtubule-associated protein, tau, which is expressed in a subset of chemotherapy-resistant breast cancers.
The results show that endogenous tau protein localizes to McTNs and is both necessary and sufficient to promote McTN extension in detached breast tumor cells. Tau-induced McTNs increase reattachment of suspended cells and retention of CTCs in lung capillaries.
Analysis of individual-matched primary and metastatic tumors reveals that 52% possess tau-expression in metastases and 26% display significantly increased tau-expression over disease progression. Tau-enrichment in metastatic tumors and the ability of tau to promote tumor cell reattachment through McTN formation support a model in which tau-induced microtubule stabilization provides a selective advantage during tumor metastasis.
“We hope that through our research, we will be able to identify drugs that will target the growth of these microtentacles and help to stop the spread of the original cancer. Drugs that reduce tau expression may hold potential to inhibit tumor metastasis,” says the senior author, Stuart S. Martin, PhD, a researcher at the University of Maryland Greenebaum Cancer Center and associate professor of physiology at the University of Maryland School of Medicine.
